ANTICOAGULANT DOSING CONVERSIONS; Conversion of DABIGATRAN ETEXILATE: Switching from DABIGATRAN to WARFARIN • Adjust starting time of warfarin based on CrCl as follows: ...

If you've been diagnosed with a deep venous thrombosis (DVT), you can expect at least three months of continued anticoagulants, or blood-thinning medications, such as warfarin, after you leave the ...

Incorporating genetic information into clinical algorithms may help clinicians better determine optimal doses of warfarin for patients who require doses higher and lower than the mean, according ...

Findings from a recent study suggests that clinical and genetic factors affecting warfarin dose requirements differ by race. The study is published in the journal Blood.Blood.

Warfarin and heparin are anticoagulant medications, or "blood thinners." They help stop your blood from clotting when it’s not necessary. Find out how the two drugs work, and how they differ.

Patients using warfarin for oral anticoagulant therapy need to be frequently monitored because of warfarin's narrow therapeutic range and the large variation in dose requirements among patients ...

For women, the median dose ranged from 6.1 mg (among those aged <50) to 3.0 mg (among those aged ≥90). About 65% of men and 81% of women older than 70 required daily doses below 5 mg.

Among 1,650 randomized patients, 97 percent received at least 1 dose of warfarin therapy and completed the trial (n = 808 in genotype-guided group vs n = 789 in clinically-guided group).

Trial will test informatics software used in Warfarin dosing. Louisville-based PGXL Laboratories has received an OK from regulators to conduct clinical trials on its informatics software, called ...

Dosing Crucial for Digoxin, Warfarin Safety — Digoxin unsafe at high levels regardless of heart failure by Nicole Lou , Staff Writer, MedPage Today March 21, 2017 • 3 min read ...

Among the 1851 patients in the efficacy analysis, oral ximelagatran at a dose of 36 mg twice daily was superior to warfarin with respect to the primary composite end point of venous ...